Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ISENTRESS HD
- Combination Antiretroviral Therapy (cART) for PBC
- Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
- Optimizing the Delivery of HIV nPEP
- QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient
- Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection
- Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation
- Renal Integrase Study
- Research In Viral Eradication of HIV Reservoirs
- Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
- Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers
- Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
- Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).
- A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)
- A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
- Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients
- RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients
- Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
- A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection
- Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- RAltegravir Switch STudy: Effects on Endothelial Recovery
- Renal Transplantation and Raltegravir in HIV-Infected Patients
- A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
- Study of Options for Second-Line Effective Combination Therapy (SELECT)
- The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age
- Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
- Levels of Raltegravir in the Female Genital Tissue
- Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers
- Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
- Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
- Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
- Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
- Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.
- Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.
- The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)
- Post-Exposure Prophylaxis in Health Care Workers
- Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
- Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
- Measurement of Plasma and Intracellular Concentrations of Raltegravir
- A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von
- Effects of Intensive cART During Acute/Early HIV Infection
- Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
- Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
- Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
- Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men
- Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
- Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
- Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
- IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
- Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
- Effect of Antacids on the Pharmacokinetics of Raltegravir
- Simplification From Protease Inhibitors to Raltegravir
- Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
- IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
- Raltegravir in the Swiss HIV Cohort Study
- Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
- Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
- Raltegravir and Atazanavir Dosing Strategy Study
- Raltegravir Activity In Lymphoid Tissues
- Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
- Pilot Study of a Raltegravir Based NRTI Sparing Regimen
- An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects
- Antiretroviral Therapy for Acute and Chronic HIV Infection
- Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
- A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women
- Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers
- A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
- Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
- Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
- Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects
- Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
- Kaletra-isentress Treatment Evaluation
- Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
- The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)
- Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
- Raltegravir Therapy for Women With HIV and Fat Accumulation
- Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
- Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
- Clinical Trial of CNS-targeted HAART (CIT2)
- Raltegravir Kaletra Pharmacokinetics
- Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
Clinical trials list
click for details